Search
Brivudine
go.drugbank.com/drugs/DB03312ApprovedInvestigationalAlthough not approved in the U.S. or Canada, it is approved in several European countries.
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalThe vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.
Rusalatide
go.drugbank.com/drugs/DB05309InvestigationalTP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Artesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
VIR201
go.drugbank.com/drugs/DB05110ExperimentalThe aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
UB-612
go.drugbank.com/drugs/DB16444InvestigationalThe UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components[L30653]. … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].